Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

e cases, some of the cells in the breast begin growing abnormally and uncontrollably. This quick division of cells may cause the cancer to spread through the breast to other parts of the body(11). The process of finding out how widespread the cancer is at initial time of diagnosis is called "staging." The stage of breast cancer is one of the most important factors in determining treatment options(3).

There are several standard treatment options for people diagnosed with breast cancer, which are based on the advancement and type of an individual's breast cancer, as well as their general health(3). For patients with advanced or metastatic breast cancer who become resistant or progress on standard therapies, treatment options are limited(2).

About Afinitor (everolimus)Afinitor® (everolimus) tablets is approved in the US for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and in the European Union (EU) for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Afinitor is also approved in the US to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Improvement in disease-related symptoms or increase in survival has not been shown. Novartis has submitted marketing applications for everolimus to the European Medicines Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and additional regulatory submissions are underway worldwide.

Afinitor is available in the US in 2.5 mg, 5 mg and 10 mg tablet strengths. With once-daily dosing, Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, b
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
(Date:6/18/2013)... ANDOVER, Mass. , June 18, 2013 ... announced the company was named Overall Performance Leader in ... Medical Equipment & Infrastructure report. Philips also received Best ... of its imaging products: Ingenuity Core 128 Computed ... iE33 ultrasound and PageWriter TC70 cardiograph. The annual Best ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2
... 2012  Based on its recent analysis of the ... recognizes Sensear with the 2012 North American Frost ... its "high-noise communication" devices, including earplugs and earmuffs ... still enabling the user to remain fully aware ...
... Carla Corkern, Chief Executive Officer at Talyst , was ... recognizes entrepreneurs whose ingenuity, hard work and perseverance have created ... originated in 1986 and has grown to 26 programs in ... the world. "Talyst is a leader in ...
Cached Medicine Technology:Frost & Sullivan Recognizes Sensear for Innovative and Effective Product Differentiation in the PPE Market 2Frost & Sullivan Recognizes Sensear for Innovative and Effective Product Differentiation in the PPE Market 3Frost & Sullivan Recognizes Sensear for Innovative and Effective Product Differentiation in the PPE Market 4
(Date:6/18/2013)... Case Medical Center clinical researchers have launched an ... will evaluate the ability of a patient,s own ... stage peripheral arterial disease (PAD). , Led ... at University Hospitals Case Medical Center,s Harrington Heart ... Case Western Reserve University School of Medicine, the ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 The July ... “The Cheater’s Guide to Getting Beach Ready,” offers a list ... to look their best in a bathing suit this summer. ... skin firming , smoothing cellulite , and more. ... Simon Ourian, Medical Director of Epione Beverly Hills, “though I ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:SimuCase avatars advance speech-language pathology training 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Skin Care – Getting Your Body Beach Ready 2
... , , WEDNESDAY, Nov. 7 (HealthDay News) -- Brain development is ... shows. , The slowdown in brain development is similar to ... Babies who require heart surgery have long been known to ... the surgery or other factors has been in debate. , ...
... Cost, language barriers often to blame, study finds , ... statin drugs are known to be effective, many patients ... factors may be to blame. , In their study, ... They found that statin discontinuation rates among more than ...
... NEWPORT NEWS, Va., Nov. 7 This past ... Opposing Compact Gamma,Cameras" were presented at the Nuclear ... The goal of the laboratory study was ... camera system in a configuration in which,the two ...
... Health Informatics, From,Foundations to Applications to Policy, ... American Medical,Informatics Association (AMIA) 31st Annual Symposium, ... in biomedical and health,informatics starts Friday. Experts ... privacy and security of electronic health information,transparency ...
... WASHINGTON, Nov. 7 Today, the release ... Reduce Teen,Pregnancy and Sexually Transmitted Disease, a report ... adolescent health, confirmed, once,again, that the $1.5 billion ... waste of taxpayer money., The report, commissioned ...
... First to Taste Missy Chase Lapine,s New Kid-Friendly, Kid-Healthy Dishes, Now Added to the ... Cynthia Sparer, executive director, Morgan Stanley ... member Family Advisory Council, Morgan ... Missy Chase Lapine, Patients and ...
Cached Medicine News:Health News:Heart Defects Can Delay Baby's Brain Development 2Health News:Heart Defects Can Delay Baby's Brain Development 3Health News:Heart Defects Can Delay Baby's Brain Development 4Health News:Many Patients Stop Taking Cholesterol-Lowering Drugs 2Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 2Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 3Health News:AMIA's 31st Annual Symposium Opens in Chicago, IL 2Health News:AMIA's 31st Annual Symposium Opens in Chicago, IL 3Health News:New Study - Same Verdict 2Health News:Sneaky Chef's Recipes Make Delicious Debut at Morgan Stanley Children's Hospital 2
... Non-Donor Screen. Vironostika HIV assays provide superior ... testing and confirmation. Vironostika HIV-1 Microelisa ... the detection of antibody to HIV-1 in ... Oral Fluid Vironostika HIV-1 Microelisa System is ...
... Rapid Immunoassay: Uni-Gold Recombigen HIV is a single ... to HIV-1 in plasma, serum and whole blood ... in point of care settings as an aid ... is suitable for use in appropriate multi-test algorithms ...
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Medicine Products: